Resmed (RMD) Stock Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RMD Analyst Ratings

Moderate Buy

5 Buy

9 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Resmed

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RMD Stock 12 Month Forecast

Average Price Target

$4,917.01

▲(28.01% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Resmed in the last 3 months. The average price target is $4,917.01 with a high forecast of $6,011.76 and a low forecast of $4,320.95. The average price target represents a 28.01% change from the last price of $3,841.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3364":"$3,364","4026":"$4,026","4688":"$4,688","5350":"$5,350","6012":"$6,012"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6011.7605056,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4917.0052544381815,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.92K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4320.9528634,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.32K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3364,4026,4688,5350,6012],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3939,4098.443115815385,4257.8862316307695,4417.329347446153,4576.772463261538,4736.215579076923,4895.658694892308,5055.1018107076925,5214.544926523077,5373.988042338462,5533.431158153846,5692.874273969231,5852.317389784615,{"y":6011.7605056,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3939,4014.2311734183218,4089.4623468366435,4164.693520254965,4239.924693673287,4315.155867091608,4390.38704050993,4465.618213928252,4540.849387346573,4616.0805607648945,4691.311734183217,4766.542907601538,4841.77408101986,{"y":4917.0052544381815,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3939,3968.380989492308,3997.7619789846153,4027.142968476923,4056.5239579692307,4085.9049474615385,4115.285936953846,4144.666926446153,4174.047915938461,4203.428905430769,4232.809894923077,4262.190884415384,4291.571873907692,{"y":4320.9528634,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5066.609,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4404.199,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4415.076,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4422.407,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4422.407,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4432.66,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4007.093,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3694.977,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3705.275,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3409.04,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3365.168,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4082,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3939,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$6,012

Average Price Target$4,917

Lowest Price Target$4,321

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Adam Maeder

Piper Sandler

$4,227.02→$4,884.56

Hold

27.17%

Upside

Reiterated

10/30/26

Resmed (RMD) Receives a Hold from Piper Sandler

Anthony Petrone

Mizuho Securities

$4,508.82→$5,072.42

Buy

32.06%

Upside

Reiterated

10/30/26

ResMed price target raised to $270 from $240 at MizuhoResMed price target raised to $270 from $240 at Mizuho

Michael Matson

Needham

―

Hold

―

Reiterated

10/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Annexon Biosciences (NASDAQ: ANNX), Resmed (NYSE: RMD) and Quest Diagnostics (NYSE: DGX)

David Rescott

Robert W. Baird

$4,471.25→$4,621.54

Hold

20.32%

Upside

Reiterated

10/30/26

ResMed price target raised to $246 from $238 at BairdResMed price target raised to $246 from $238 at Baird

David Bailey

Morgan Stanley

$4,377.31

Hold

13.96%

Upside

Reiterated

10/30/26

Analysts Conflicted on These Healthcare Names: Sanofi (Other OTC: SNYNF) and Resmed (NYSE: RMD)

Laura Sutcliffe

Citi

$4,508.82→$5,072.42

Hold

32.06%

Upside

Reiterated

10/30/26

ResMed price target raised to $270 from $240 at CitiResMed price target raised to $270 from $240 at Citi

Brett Fishbin

KeyBanc

$5,016.06→$5,203.93

Buy

35.48%

Upside

Reiterated

10/30/26

Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Encompass Health (EHC)

Nathan Treybeck

Wells Fargo

$4,039.15→$4,696.69

Hold

22.28%

Upside

Assigned

10/30/26

Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD), BridgeBio Pharma (NASDAQ: BBIO) and Kymera Therapeutics (NASDAQ: KYMR)

Craig Wong-Pan

RBC Capital

$4,922.13→$5,410.58

Buy

40.86%

Upside

Reiterated

10/30/26

RBC Capital Remains a Buy on Resmed (RMD)

Lyanne Harrison

Bank of America Securities

$6,011.76

Buy

56.52%

Upside

Reiterated

10/13/26

Analysts Conflicted on These Healthcare Names: Resmed (NYSE: RMD) and Bristol-Myers Squibb (NYSE: BMY)

Jonathan Block

Stifel Nicolaus

$4,414.89

Hold

14.94%

Upside

Reiterated

10/02/26

Stifel Nicolaus Sticks to Its Hold Rating for Resmed (RMD)

Jackson Philips

Rothschild & Co Redburn

Not Ranked

Rothschild & Co Redburn

$4,320.95

Hold

12.50%

Upside

Initiated

08/19/26

ResMed initiated with a Neutral at Rothschild & Co RedburnResMed initiated with a Neutral at Rothschild & Co Redburn

Unknown Analyst

Oppenheimer

Not Ranked

Oppenheimer

―

Hold

―

Assigned

08/07/26

Oppenheimer Issues a Hold Rating on Resmed (RMD)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

08/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Resmed (NYSE: RMD) and DENTSPLY SIRONA (NASDAQ: XRAY)

Matthew Taylor

Jefferies

$4,227.02

Hold

10.05%

Upside

Reiterated

07/10/26

Jefferies Issues a Hold Rating on Resmed (RMD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Adam Maeder

Piper Sandler

$4,227.02→$4,884.56

Hold

27.17%

Upside

Reiterated

10/30/26

Resmed (RMD) Receives a Hold from Piper Sandler

Anthony Petrone

Mizuho Securities

$4,508.82→$5,072.42

Buy

32.06%

Upside

Reiterated

10/30/26

ResMed price target raised to $270 from $240 at MizuhoResMed price target raised to $270 from $240 at Mizuho

Michael Matson

Needham

―

Hold

―

Reiterated

10/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Annexon Biosciences (NASDAQ: ANNX), Resmed (NYSE: RMD) and Quest Diagnostics (NYSE: DGX)

David Rescott

Robert W. Baird

$4,471.25→$4,621.54

Hold

20.32%

Upside

Reiterated

10/30/26

ResMed price target raised to $246 from $238 at BairdResMed price target raised to $246 from $238 at Baird

David Bailey

Morgan Stanley

$4,377.31

Hold

13.96%

Upside

Reiterated

10/30/26

Analysts Conflicted on These Healthcare Names: Sanofi (Other OTC: SNYNF) and Resmed (NYSE: RMD)

Laura Sutcliffe

Citi

$4,508.82→$5,072.42

Hold

32.06%

Upside

Reiterated

10/30/26

ResMed price target raised to $270 from $240 at CitiResMed price target raised to $270 from $240 at Citi

Brett Fishbin

KeyBanc

$5,016.06→$5,203.93

Buy

35.48%

Upside

Reiterated

10/30/26

Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Encompass Health (EHC)

Nathan Treybeck

Wells Fargo

$4,039.15→$4,696.69

Hold

22.28%

Upside

Assigned

10/30/26

Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD), BridgeBio Pharma (NASDAQ: BBIO) and Kymera Therapeutics (NASDAQ: KYMR)

Craig Wong-Pan

RBC Capital

$4,922.13→$5,410.58

Buy

40.86%

Upside

Reiterated

10/30/26

RBC Capital Remains a Buy on Resmed (RMD)

Lyanne Harrison

Bank of America Securities

$6,011.76

Buy

56.52%

Upside

Reiterated

10/13/26

Analysts Conflicted on These Healthcare Names: Resmed (NYSE: RMD) and Bristol-Myers Squibb (NYSE: BMY)

Jonathan Block

Stifel Nicolaus

$4,414.89

Hold

14.94%

Upside

Reiterated

10/02/26

Stifel Nicolaus Sticks to Its Hold Rating for Resmed (RMD)

Jackson Philips

Rothschild & Co Redburn

Not Ranked

Rothschild & Co Redburn

$4,320.95

Hold

12.50%

Upside

Initiated

08/19/26

ResMed initiated with a Neutral at Rothschild & Co RedburnResMed initiated with a Neutral at Rothschild & Co Redburn

Unknown Analyst

Oppenheimer

Not Ranked

Oppenheimer

―

Hold

―

Assigned

08/07/26

Oppenheimer Issues a Hold Rating on Resmed (RMD)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

08/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Resmed (NYSE: RMD) and DENTSPLY SIRONA (NASDAQ: XRAY)

Matthew Taylor

Jefferies

$4,227.02

Hold

10.05%

Upside

Reiterated

07/10/26

Jefferies Issues a Hold Rating on Resmed (RMD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AORTArtivion

MDWDMediwound

IMUXImmunic

RZLTRezolute

DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Resmed

3 Months

Brett FishbinKeyBanc

Success Rate

9/16 ratings generated profit

Average Return

+2.15%

Copying Brett Fishbin's trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +2.15% per trade.

1 Year

Lyanne HarrisonBank of America Securities

Success Rate

19/29 ratings generated profit

Average Return

+9.26%

Copying Lyanne Harrison's trades and holding each position for 1 Year would result in 65.52% of your transactions generating a profit, with an average return of +9.26% per trade.

2 Years

Lyanne HarrisonBank of America Securities

Success Rate

16/29 ratings generated profit

Average Return

+12.32%

Copying Lyanne Harrison's trades and holding each position for 2 Years would result in 55.17% of your transactions generating a profit, with an average return of +12.32% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RMD Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RMD has received 10 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. RMD average Analyst price target in the past 3 months is 4,917.01.

Each month's total comprises the sum of three months' worth of ratings.

RMD Financial Forecast

RMD Earnings Forecast

Next quarter’s earnings estimate for RMD is $56.27 with a range of $55.05 to $58.24. The previous quarter’s EPS was $54.67. RMD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RMD has Performed in-line its overall industry.

RMD Sales Forecast

Next quarter’s sales forecast for RMD is $27.36B with a range of $27.00B to $27.79B. The previous quarter’s sales results were $26.58B. RMD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RMD has Performed in-line its overall industry.

RMD Stock Forecast FAQ

What is MX:RMD’s average 12-month price target, according to analysts?

Based on analyst ratings, Resmed’s 12-month average price target is 4,917.01.

What is MX:RMD’s upside potential, based on the analysts’ average price target?

Resmed has 28.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Resmed a Buy, Sell or Hold?

Resmed has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 9 hold ratings and 0 sell ratings.

What is Resmed’s share price target?

The average share price target for Resmed is 4,917.01. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $6,011.76 ,and the lowest forecast is $4,320.95. The average share price target represents 28.01% Increase from the current price of $3,841.

What do analysts say about Resmed?

Resmed’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Resmed?

To buy shares of MX:RMD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Resmed (RMD) Stock Forecast & Price Target

RMD Analyst Ratings

RMD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Resmed

RMD Analyst Recommendation Trends

RMD Financial Forecast

RMD Earnings Forecast

RMD Sales Forecast

RMD Stock Forecast FAQ

Detailed List of Analyst Forecasts